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Abstract
Background: Despite an ever-improving understanding of the molecular biology of cancer, the treatment of most
cancers has not changed dramatically in the past three decades and drugs that do not discriminate between
tumor cells and normal tissues remain the mainstays of anticancer therapy. Since Hsp90 is typically involved in cell
proliferation and survival, this is thought to play a key role in cancer, and Hsp90 has attracted considerable interest
in recent years as a potential therapeutic target.
Methods: We focused on the interaction of Hsp90 with its cofactor protein p60/Hop, and engineered a cell-
permeable peptidomimetic, termed “hybrid Antp-TPR peptide”, modeled on the binding interface between the
molecular chaperone Hsp90 and the TPR2A domain of Hop.
Results: It was demonstrated that this designed hybrid Antp-TPR peptide inhibited the interaction of Hsp90 with the
TPR2A domain, inducing cell death of breast, pancreatic, renal, lung, prostate, and gastric cancer cell lines in vitro.
In contrast, Antp-TPR peptide did not affect the viability of normal cells. Moreover, analysis in vivo revealed that Antp-
TPR peptide displayed a significant antitumor activity in a xenograft model of human pancreatic cancer in mice.
Conclusion: These results indicate that Antp-TPR peptide would provide a potent and selective anticancer therapy
to cancer patients.
Background
Heat-shock protein 90 (Hsp90) is a molecular chaperone
[1] that participates in the quality control of protein fold-
ing. The mechanism of action of Hsp90 includes sequen-
tial ATPase cycles and the stepwise recruitment of
cochaperones, including Hsp70, CDC37, p60/Hsp-orga-
nizing protein (Hop), and p23 [2,3]. In particular, Hsp90
and Hsp70 interact with numerous cofactors containing
so-called tetratricopeptide repeat (TPR) domains. TPR
domains are composed of loosely conserved 34-amino
acid sequence motifs that are repeated between one and
16 times per domain. Originally identified in components
of the anaphase-promoting complex [4,5], TPR domains
are now known to mediate specific protein interactions
in numerous cellular contexts [6-8]. Moreover, apart
from serving mere anchoring functions, TPR domains of
the chaperone cofactors Hip and p60/Hop also are able
to regulate the ATPase activities of Hsp70 and Hsp90,
respectively [9,10]. Each 34-amino acid motif forms a
pair of antiparallel a-helices. These motifs are arranged
in a tandem array into a superhelical structure that
encloses a central groove. The TPR-domain-containing
cofactors of the Hsp70/Hsp90 multi-chaperone system
interact with the C-terminal domains of Hsp70 and
Hsp90 [11]. Studies involving deletion mutagenesis have
suggested that the C-terminal sequence motif EEVD-
COOH, which is highly conserved in all Hsp70s and
Hsp90s of the eukaryotic cytosol, has an important role
in TPR-mediated cofactor binding [12]. Hop serves as an
adapter protein for Hsp70 and Hsp90 [13,14], optimizing
their functional cooperation [15] without itself acting as a
molecular chaperone [16], and contains three TPR
domains, each comprising three TPR motifs [17]. The
N-terminal TPR domain of Hop, TPR1, specifically recog-
nizes the C-terminal seven amino acids of Hsp70
(PTIEEVD), whereas TPR2A recognizes the C-terminal
five residues of Hsp90 (MEEVD) [17].
Hsp90 has a restricted repertoire of client proteins; for
example, several kinases, among other proteins, that
bind to Hsp90 for proper maturation, and Hsp90 is
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This is thought to play a key role in cancer [18-20], in
which the stress-response recognition of Hsp90 may
help promote tumor-cell ad a p t a t i o ni nu n f a v o r a b l e
environments [21]. Understanding of this pathway has
created a viable therapeutic opportunity [22], and mole-
cular targeting of Hsp90 ATPase activity by the class of
ansamycin antibiotics prototypically exemplified by gel-
danamycin [23] has shown promising anticancer activity
by disabling multiple signaling networks required for
tumor-cell maintenance [24]. Although many Hsp90-tar-
geted compounds are being examined for anticancer
therapeutic potential, the molecular mechanism of their
anticancer activity is still unclear. Recently, Gyurkocza
et al. reported a novel peptidyl antagonist of the interac-
tion between Hsp90 and survivin, and designated it
“shepherdin” [25,26]. Survivin is a member of the inhibi-
tor of apoptosis gene family [27] and is involved in the
control of mitosis and the suppression of apoptosis or
cell death [28]. It is demonstrated that shepherdin
makes extensive contacts with the ATP pocket of
Hsp90, destabilizes its client proteins, and causes mas-
sive death of cancer cells by apoptotic and nonapoptotic
mechanisms. Strikingly, shepherdin does not reduce the
viability of normal cells [25,26]. These results indicate
that not only small compounds but also peptides target-
ing Hsp90 would provide potent antitumor selectivity in
a cancer-bearing host.
In this study we designed a novel hybrid peptide con-
sisting of cell-membrane-penetrating and Hsp90-tar-
geted sequences. Structure-based mimicry to disrupt the
interaction between Hsp90 and the TPR2A domain of
Hop was demonstrated, as were the efficacies in vitro
and in vivo of this peptide drug against cancer.
Methods
Materials
Anti-Hsp90 and anti-Hsp70 antibodies, human recombi-
nant Hsp90a, and Hop (p60) were purchased from
Stressgen Bioreagents. Anti-Akt and anti-CDK4 antibo-
dies were purchased from Cell Signaling. Anti-survivin
antibody was purchased from Thermo Scientific.
Human recombinant FKBP5 and PP5 were purchased
from Abnova. Anti-b-actin antibody and human recom-
binant Hsp70 were purchased from SIGMA. All
reagents were of reagent-grade quality.
Strain and plasmid
Escherichia coli AD494 (DE3) {Δara, leu 7697, ΔlacX74,
ΔphoA, PvuII, PhoR, ΔmalF3, F’ [lac
-,( lacI
q), pro], trxB::
kan (DE3)} and pET-15b (Novagen Inc.) were used for
expression of the TPR2A domain of human Hop.
Cell culture
The following human tumor and normal cell lines were
obtained from the American Type Culture Collection
(ATCC): human breast cancer (BT-20, T47D, and MDA-
MB-231), lung cancer (A549), kidney cancer (Caki-1),
prostate cancer (LNCap), gastric cancer (OE19) and lung
fibroblast (MRC5). Human pancreatic cancer cell line
(BXPC3) was purchased from the European Collection of
Cell Culture (ECACC). Human embryonic kidney cell
line (HEK293T) and human normal pancreatic epithelial
(PE) cell line ACBRI 515 were purchased from RIKEN
cell bank and DS Pharma Biomedical, respectively. Cells
were cultured in RPMI-1640 (BT-20, MDA-MB-231,
T47D, LNCap, OE19, and BXPC3), MEM (MRC5 and
A549), DMEM (HEK293T and Caki-1) or CSC (PE) con-
taining 10% fetal bovine serum (FBS), 100 μg/ml penicil-
lin, and 100 μg/ml streptomycin.
Peptide synthesis
Peptides used in this study were synthesized by Invitrogen
or SIGMA. All peptides were synthesized by use of solid-
phase chemistry, purified to homogeneity (i.e. >90% purity)
by reversed-phase high-pressure liquid chromatography,
and assessed by mass spectrometry. Peptides were dis-
solved in water and buffered to pH 7.4. The TPR sequence
301K-312K (KAYARIGNSYFK; TPR), TPR mutant 1
(KAYAAAGNSYFK; mutated amino acids are underlined),
TPR mutant 2 (KAYARIGNSGGG), and scramble peptide
(RKFSAAIGYNKY) were made cell-permeable by addition
of helix III of the cell-penetrating Antennapedia homeodo-
main sequence (underlined below) [29], as follows: RQI-
KIWFQNRRMKWKKKAYARIGNSYFK (Antp-TPR),
RQIKIWFQNRRMKWKKKAYAAAGNSYFK (Antp-TPR
mutant 1), RQIKIWFQNRRMKWKKKAYARIGNSGGG
(Antp-TPR mutant 2), and RQIKIWFQNRRMKWKKRKF-
SAAIGYNKY (Antp-scramble).
Expression and purification of the TPR2A domain of
human Hop
The TPR2A domain (223K-352L) of human Hop was
cloned in-frame into the XhoIa n dBamHI sites of pET-
15b for expression in E. coli AD494 (DE3), and purified
using a nickel-chelating resin column as described pre-
v i o u s l y[ 3 0 ] .T oc o n f i r mt h ep r e s e n c eo fp u r i f i e dp r o -
tein, SDS/PAGE was performed according to the
method of Laemmli [31].
Surface plasmon resonance (SPR)
SPR experiments were performed with the Biacore bio-
sensor 3000 system as described previously [30,32].
Human recombinant Hop, FKBP5, PP5, and purified
TPR2A domain of Hop proteins were immobilized on
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mide and N-ethyl-N’-(dimethylaminopropyl)carbodiimide
activation chemistry according to the manufacturer’s
instructions. Biotin-conjugated TPR peptide (biotin-TPR)
was immobilized on the surface of streptavidin (SA) sen-
sor chip. As the analyte, several concentrations of Hsp90
or Hsp70 were injected over the flow-cell at a flow rate
30 μl/min at 25°C. HBS-EP buffer (0.01 M Hepes/0.15 M
NaCl/0.005% Tween 20/3 mM EDTA, pH 7.4) was
used as a running buffer during the assay to inhibit non-
specific binding. Data analysis was performed using BIA
evaluation version 4.1 software. Competition experiments
were performed by preincubating Hsp90 or Hsp70 with
short, defined peptides or combinatorial peptide mixtures
according to the method of Brinker et al. [30]. Briefly,
protein/peptide mixtures were passed over the immobi-
lized Hop, FKBP5, PP5 or TPR2A domain of Hop, and
bindings of Hsp90 or Hsp70 to these proteins were fol-
lowed. SPR signals obtained in the absence of competing
peptides were used as a reference (100% binding) to nor-
malize values obtained in the presence of peptides. For
competition experiments involving defined peptides the
concentration of TPR protein was kept constant, whereas
the peptide concentration of the protein/peptide mix-
tures was increased systematically.
Western blotting
Western-blot analyses were carried out as described pre-
viously [33]. Briefly, protein extracts were prepared from
cells lysed with buffer containing 1% (v/v) Triton X-100,
0.1% (w/v) SDS, and 0.5% (w/v) sodium deoxycholate,
separated by SDS/PAGE, and transferred to nitrocellu-
lose filters. Quenched membranes were probed with
antibodies and analyzed using enhanced chemilumines-
cence reagent (GE Healthcare) with an LAS-3000 Lumi-
noImage analyzer (Fujifilm).
Assay for cell viability
Cells were seeded on to 96-well plates at 2000-3000
cells/well and incubated with the test peptide. After
incubation, an assay for cell viability was carried out
using Living Cell Count Reagent SF (Nacalai Tesque)
according to the manufacturer’s protocol. Absorbance
was measured at a wavelength of 450 nm using a
96-well microplate reader (GE Healthcare).
Fluorescent microscopy
BXPC3 cells were plated in a glass-bottomed dish at 1 ×
10
6 cells per ml of medium, and small aliquots of
labeled-peptides, Antp-TPR-TAMRA-OH or TPR-
TAMRA-OH (Invitrogen) (15 μl) were added directly
into the dish at a final concentration of 10 μM. After
2 hr incubation, intracellular penetration of the peptides
was visualized by an Olympus FV1000 confocal laser
scanning microscope (Olympus).
Flow cytometry assay
After incubation with or without Antp-TPR peptide, cells
were collected and washed twice with PBS. Following
this, the cell pellets were resuspended. Flow cytometry
(Becton Dickinson) analysis was performed using the
Annexin V-Fluorescein Staining Kit (Wako) or carboxy-
fluorescein FLICA caspase 3 & 7 assay kit (immuno-
chemistry Technologies) according to the manufacturer’s
protocol. Data were analyzed using CellQuest Software.
Antitumor activity of Antp-TPR peptide in tumor
xenografts in vivo
Animal experiments were carried out in accordance
with the guidelines of the Kyoto University School of
Medicine. Cells of the pancreatic cancer cell line BXPC3
(5×10
6 cells), resuspended in 150 μlo fP B S ,w e r et r a n s -
planted subcutaneously into the flank region of 7-9-
w e e k - o l da t h y m i cn u d em i c ew e i g h i n g1 7 - 2 1g .W h e n
tumors reached around 50 mm
3 in volume, animals
were randomized into three groups, and PBS (control)
or Antp-TPR peptide (1 or 5 mg/kg) was injected intra-
venously (50 μl/injection) three times a week for a total
of nine doses. Tumors were measured with a caliper,
and the tumor volume (in mm
3) was calculated using
the following formula: length×width
2×0.5. All values are
expressed as the mean ± SD and statistical analysis was
calculated by a one-way ANOVA with Dunnett test. Dif-
ferences were considered to be significance at P < 0.05.
Immunohistochemistry
Immunohistochemical staining was performed as
described previously [34]. Briefly, BXPC3 tumor from
animals treated either with saline or Antp-TPR peptide
(5 mg/kg) intravenously were harvested at the end of
treatment, and subsequently embedded in paraffin after
fixation with 10% formaldehyde in PBS. After deparaffi-
nized and hydrated, tumor sections were treated with
antibodies, and then peroxidase activity was detected by
incubation in 0.05% of 3, 3’-diaminobenzidine tetra-
chloride in PBS (pH7.2) containing 0.012% of H2O2.
Results
Design of TPR peptide
It is well known that the functional form of Hsp90 is a
complex in which the chaperones Hsp90 and Hsp70 are
brought together by binding to Hop [14] and assembly
of this multiprotein complex is achieved by means of
two independent TPR1 and TPR2A domains on Hop. In
the complex of TPR2A and C-terminal region of Hsp90,
Lys 301 and Arg 305 in helix A3 of TPR2A donate
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Glu of the Hsp90 C-terminal region [17]. In addition,
Arg 305 in helix A3 is highly conserved among other
TPR domains [17], and mutation of this Arg residue to
Ala in the TPR domain of Tom70 is critical for binding
to Hsp90 [35]. Based on these information, we designed
a new TPR peptide, KAYARIGNSYFK, which includes
the significant and highly conserved amino acids Lys
301 and Arg 305 for binding to Hsp90, using structural
information obtained from the TPR2A-Hsp90 complex
(Figure 1A). As shown in Figure 1(B), both Hsp90 and
Hsp70 bind to the immobilized TPR peptide, and with
similar KD values, 1.42 × 10
-6 (M) and 0.68 × 10
-6 (M)
at increasing ligand concentrations, respectively, but the
relative binding ability of Hsp70 to TPR peptide for
Hsp90 was 49.9% (data not shown). In addition, the KD
value of the interaction of Hsp90 with Hop was also
similar (4.43 × 10
-6 (M), data not shown). It was found
that the TPR peptide did not inhibit the interaction of
Hsp70 with Hop protein as assessed by Biacore biosen-
sor (Figure 1C), and that this peptide also did not affect
the interaction of Hsp90 with FKBP5 or PP5 proteins
Figure 1 Design and characterization of TPR peptide. (A) Predicted structure of designed TPR peptide. The designed TPR peptide
obtained from helix A3 of the TPR2A domain and the bound C-terminal region of Hsp90 are shown with stick model using Ras Mol software.
Each number indicates the position of amino acids in Hop or Hsp90 proteins. (B) Sensorgrams of Hsp90 or Hsp70 bound to immobilized TPR
peptide as determined using the Biacore biosensor. All analytes (0.3, 1, or 2 μM of Hsp90 or Hsp70) were injected over TPR peptide. The
progress of binding to immobilized TPR peptide was monitored by following the increase in signal (response) induced by analytes. The thin and
thick arrows indicate the start and stop injection, respectively. RU indicates resonance unit. (C) Competition assay for Hsp70 binding to Hop by
TPR peptide. Hsp70 (1 μM) was passed over immobilized Hop in the absence (Control) or presence of TPR peptide (700 μM). The SPR signal in
the absence of competing peptides was used as a reference (100% binding). Thin and thick arrows indicate start and stop injections,
respectively. Equilibrium response levels obtained in the presence of competing peptides - TPR peptide was normalized and plotted against the
peptide concentrations as described in the Materials and Methods section (inset graph). (D) Competition for Hsp90 binding to Hop, FKBP5, or
PP5 with TPR peptide. Hsp90 (1 μM) was passed over immobilized Hop, FKBP5, or PP5 in the absence or presence of increasing concentrations
of TPR peptide (14, 140, or 700 μM). The SPR signal in the absence of competing peptides was used as a reference (100% Hsp90 binding).
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domain as described previously [17]. However, it was
shown that TPR peptide inhibited the interaction of
Hsp90 with Hop protein (Figure 1D). The designated
TPR peptide was further fused by its N-terminus to
helix III of the Antennapedia homeodomain protein [29]
to generate a cell-permeable variant, hybrid Antp-TPR
peptide, as described in the Materials and Methods
section.
Selectivity of hybrid Antp-TPR and the significance of
highly conserved amino acids in TPR peptide for
anticancer activity
Based on analysis of the interaction of the designed
hybrid Antp-TPR peptide with human Hsp90 protein,
we then examined cancer-cell viability to assess the
selectivity of this peptide in discriminating between nor-
mal and cancer cells. As shown in Figure 2(A), the
Antp-TPR peptide caused a concentration-dependent
loss of human cancer cell viability (in the Caki-1,
BXPC3, T47D, and A549 cell lines); however, identical
concentrations of this peptide did not apparently reduce
the viability of normal human cell lines (HEK293T,
MRC5, and PE) (Figure 2A), and TPR peptide without
Antp, the cell-permeable peptide, had no effect on nor-
mal or cancer cells (Figure 2B). Confocal microscopy
analysis also demonstrated that Antp-TPR peptide
labeled with TAMRA penetrated the cancer cells,
whereas TPR-TAMRA peptide without Antp sequence
did not penetrate to cancer cells (Additional file 1). In
addition, Antp-scramble peptide had no effect on these
cell lines (data not shown). For the cancer cell lines
Figure 2 Designed hybrid Antp-TPR peptide demonstrates selectivity for cancer-cell killing. (A) The indicated cancer or normal cell lines
were incubated with Antp-TPR peptide. (B) TPR peptide needs to be combined with Antp, the cell-penetrating peptide, to have a selective cell-
killing effect. (C, D) Mutation analysis of TPR peptide examining its effect on cell killing. The indicated cell lines were incubated with Antp-TPR
mutant 1 (C), in which highly conserved Arg and the subsequent amino acid, Ile, in the TPR peptide were replaced with Ala, or mutant 2
peptide (D), in which last three amino acids of TPR, Tyr-Phe-Lys, were replaced with three Gly residues to disrupt the helix structure of TPR. All
cell viability was analyzed after 72 h incubation of test peptides as described Materials and Methods section. Data represent the mean ± SD
from experiments performed in triplicate.
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between 20 and 60 μM. On the other hand, TPR peptide
showed no cytotoxicity towards either these cancer cell
lines or normal cells (Table 1). These results demon-
strate that the TPR peptide combined with Antp, a cell-
permeable peptide, has selective anticancer activity that
discriminates between normal and tumor cells. In addi-
tion, as shown in Figure 2(C) and 2(D), Antp-TPR
mutant 1 and 2 peptides did not show selective antitu-
mor activities when these peptides were tested with
both normal and cancer cell lines. This suggests that the
mutated amino acids in Antp-TPR mutants 1 and 2 are
indispensable for the selective antitumor activity of
Antp-TPR.
Competition for TPR2A-mediated protein interactions by
the designed TPR peptide
We further investigated whether the designed TPR pep-
tide was able to compete specifically for the interaction
of Hsp90 with the TPR2A domain of Hop, which is
necessary for the correct folding of several oncogenic
proteins in cancer cells [18-20]. Hsp90 was passed over
a sensor chip carrying immobilized purified recombinant
TPR2A domain of human Hop in either the absence or
presence of increasing concentrations of TPR peptide
(Figure 3). The SPR signal in the absence of peptide
competitor was used as a reference (100% binding) to
normalize the signals for Hsp90 binding recorded in the
presence of peptide. The interaction of the TPR2A
domain of Hop with Hsp90 was competed for by TPR
peptide (Figure 3A and 3C). In contrast, the TPR scram-
ble peptide and TPR mutant peptides 1 and 2 did not
demonstrate any protein interaction when analyzed at
up to millimolar concentrations (Figure 3B and 3C).
These results indicate that the designed TPR peptide is
a specific competitor capable of inhibiting the interac-
tion between Hsp90 and the TPR2A domain of Hop,
and that the amino acids targeted in our mutagenesis
experiment are critical for this protein interaction to
occur.
Characterization of cancer cell killing and loss of client
proteins by Antp-TPR peptide
As mentioned previously, the interaction of Hsp90 with
Hop in cancer cells is significant for folding of several
oncogene proteins including survivin, which is a member
of the inhibitor of apoptosis gene family [27]. In addition,
Antp-TPR has selective cytotoxic activity towards cancer
cells and is an inhibitor of the interaction of Hsp90 with
the TPR2A domain of Hop (Figures 2 and 3). These
results prompted us to investigate whether Antp-TPR
induces apoptosis in cancer cells. As assessed by flow
cytometry analysis, annexin V or caspase 3 and 7 positive
cells were found when Antp-TPR peptide was added to
breast cancer T47D cells (Figure 4A, middle and right
lane panels), suggesting that this peptide induces cancer
cell death by apoptotic mechanism (Figure 4A, middle
and right lane panels). On the other hand, there was no
appearance of annexin V-labeled HEK293T cells after
addition of this hybrid peptide (Figure 4A, left lane
panels). Taken together with Figures 2 and 3, it was
shown that the Antp-TPR peptide designed in this study
provided selectivity to cancer cells, discriminating
between normal and cancer cells.
When we examined the levels of Hsp90 client proteins
after intracellular loading of Antp-TPR peptide, T47D
cells treated with Antp-TPR exhibited loss of multiple
Hsp90 client proteins, including survivin, CDK4, and
Akt, as assessed by Western blotting (Figure 4B). In
contrast, Antp-TPR peptide did not affect the levels of
Hsp90 itself (Figure 4B). When normal and cancer cell
lines (HEK293T, Caki-1, BXPC3, T47D, and A549)
received heat shock, the up-regulation of Hsp90 and
Hsp70 was observed in the cancer cells, but not in nor-
mal HEK293T cells (Additional file 2A). In addition, the
up-regulation of Hsp70 after the treatment with this
peptide was not observed in both cancer and normal
cell lines (Additional file 2B). When we investigated the
expression levels of Hsp90, Hsp70, and survivin in these
cell lines using Western blotting, it was found that the
expression of Hsp90 was almost equal between normal
and cancer cells, however, survivin was highly expressed
Table 1 Inhibitory concentration (IC50) of the Antp-TPR
Antitumor activity, IC50 (μM) *
Cell lines TPR Antp-TPR
Normal cells
HEK293T - >100
MRC5 - >100
PE - >100
Breast cancer
T47D - 19.4
BT20 - 37.4
MDA-MB-231 - 56.9
Pancreatic cancer
BXPC3 - 44.8
Renal cancer
Caki-1 - 47.9
Lung cancer
A549 - 65.9
Prostate cancer
LNcap - 56.7
Gastric cancer
OE19 - 33.4
* Results are the mean of three independent experiments each performed in
triplicate.- indicates no effect.
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was different among these cell lines (Figure 4C). These
results suggest that the Antp-TPR peptide designed in
this study would affect the cell-survival pathways in can-
cer cells by competing with cochaperone recruitment,
which is indispensable for the correct folding of Hsp90
client proteins.
Antitumor activity of Antp-TPR peptide in vivo
To assess the antitumor effect of Antp-TPR peptide in
a xenograft model of human cancer, BXPC3 pancreatic
cancer cells were implanted subcutaneously into athy-
mic nude mice and the animals were treated with
Antp-TPR peptide. The control group exhibited pro-
gressive tumor growth, reaching 749 mm
3 at day 58
(Figure 5A). On the other hand, administration of
Antp-TPR peptide (1 or 5 mg/kg, administered intrave-
nously three times a week for 3 weeks) suppressed
tumor growth remarkably. On day 58, mean tumor
volume was 371 mm
3 in 1 mg/kg dosage group and
204 mm
3 in 5 mg/kg dosage group (P <0 . 0 5c o m p a r e d
with control group) (Figure 5A). Immunohistochemical
staining also demonstrated that Antp-TPR peptide
caused loss of Hsp90 client protein (CDK4) in BXPC3
tumors in vivo after the treatment, although tumors
from the saline group exhibited extensive labeling for
this protein (Figure 5B). In addition, histologic exami-
nation of liver, kidney, and lung was equally unremark-
able in the saline or hybrid peptide-treated mice
(Figure 5C). These results suggest that the newly
designed hybrid Antp-TPR peptide successfully induces
tumor death via loss of Hsp90 client proteins in vivo.
Figure 3 Competition for Hsp90 binding to the TPR2A domain of Hop.H s p 9 0( 1μM) was passed over immobilized TPR2A domain of
human Hop (5000 resonance units [RU]) in the absence or presence on increasing concentrations of TPR (A) or TPR scramble (B) peptide (1.4,
14, 140, 280, and 700 μM, and 1 mM). The SPR signal in the absence of competing peptides was used as a reference (100% binding). (C)
Equilibrium response levels obtained in the presence of competing peptides - TPR (KAYARIGNSYFK), TPR scramble (RKFSAAIGYNKY), TPR mutant 1
(KAYAAAGNSYFK), or TPR mutant 2 (KAYARIGNSGGG) - were normalized and plotted against the peptide concentrations as described in the
Materials and Methods section.
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treated with (+) or without (-) Antp-TPR peptide (68 μM) were analyzed after 24 h by dual-color flow cytometry for annexin V (left and middle
lane panels) or caspase 3 and 7 (right lane panels) labeling in the green channel, and propidium iodide (PI) staining in the red channel as
described in the Materials and Methods section. The percentage of cells in each quadrant is indicated, and the experiments were performed
twice with similar results. (B) Loss of Hsp90 client proteins. T47D cells were incubated with Antp-TPR peptide (68 μM) for 48 h and analyzed by
Western blotting with the indicated antibodies. (C) Western-blot analysis of Hsp90, Hsp70, and survivin expression in the normal and cancer cell
lines HEK293T, Caki-1, BXPC3, T47D, and A549. Cell extracts from these cell lines were examined for protein expression by Western-blot analysis.
b-actin was used as the loading control.
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In this study, we designed, identified, and characterized
TPR peptide, a novel anticancer peptidomimetic modeled
on the binding interface between Hsp90 and the TPR2A
domain of Hop. As demonstrated in a recent structure-
based approach, TPR2A discriminates between the C-
terminal five residues of Hsp90 (MEEVD) and the C-
terminal sequence of Hsp70 (PTIEEVD) with its main six
h e l i c e s( A 1 ,B 1 ,A 2 ,B 2 ,A 3 ,a n dB 3 )[ 1 7 , 3 0 ] .I nt h e s e
helices, Lys 301 and Arg 305 of helix A3 are especially
critical for their respective interaction by hydrogen bond-
ing with the side chains of the Asp and Glu residues of
the Hsp90 C-terminal peptide [17]. This information
prompted us to design a peptide using the TPR2A
domain of Hop, including the highly conserved Arg 305
residue of helix A3, that could compete for interaction
with Hsp90, and to test the cytotoxicity of this peptide in
vitro and its antitumor activity in vivo. Interestingly, both
Hsp90 and Hsp70 were able to bind the designed TPR
peptide (Figure 1B), however, the relative binding ability
of Hsp70 to this peptide was lower than that of Hsp90,
and this peptide failed to inhibit the interaction of Hsp70
with Hop protein (Figure 1C) and the interaction of
Hsp90 with FKBP5 or PP5 (Figure 1D). In addition, TPR
peptide inhibited the interaction of Hsp90 with Hop spe-
cifically. These results suggest that the designed peptide
in this study is specific inhibitor to the interaction of
Hsp90 with Hop protein. As shown in Figure (2A and
2B) and Additional file 1, the designed hybrid Antp-TPR
peptide, with its cell-permeable sequence derived from
Figure 5 Antitumor activity of hybrid Antp-TPR peptide in vivo. (A) BXPC3 pancreatic cancer cells were implanted subcutaneously into
athymic nude mice. Intravenous injection of either PBS (control) or Antp-TPR peptide (1 or 5 mg/kg) was provided from day 4 as indicated by
the arrows. Each group had six animals (n = 6), and experiments were repeated twice. Data are expressed as mean ± SD. (B) Loss of Hsp90
client protein (CDK4) in tumors treated with Antp-TPR peptide in vivo. BXPC3 tumors from saline or Antp-TPR peptide (5 mg/kg) treated animals
were harvested at the end of treatment and analyzed with antibody to CDK4 by immunohistochemistry. Scale bars, 25 μm. (C) Histologic
examination after treatment with Antp-TPR hybrid peptide. Images (x400 magnification) of liver, kidney, and lung from mice after treatment with
saline (control), or Antp-TPR peptide (5 mg/kg) nine times were obtained by staining with hematoxylin and eosin (H & E).
Horibe et al. Journal of Translational Medicine 2011, 9:8
http://www.translational-medicine.com/content/9/1/8
Page 9 of 12the Antennapedia homeodomain, demonstrated selective
antitumor activity, discriminating between normal and
cancer cells. It was also demonstrated that mutating the
TPR peptide by replacing the highly conserved Arg resi-
due and the subsequent Ile in TPR2A helix A3 with dou-
ble Ala (mutant 1) caused it to lose both its ability to
inhibit the Hsp90-TPR2A interaction and its antitumor
activity (Figures 2B, C, and 3). Another TPR peptide
mutation, in which Tyr-Phe-Lys was replaced with triple
Gly to disrupt the helical structure (mutant 2), turned
out to have an effect similar to that of mutant 1, suggest-
ing that these amino acids are critical for both inhibition
and antitumor activities.
Interestingly, Antp-TPR peptide was cancer cell-
specific in its cytotoxic activities and less cytotoxic to
normal cells including HEK293T, PE, and MRC5
(Figure 2A), although the expression levels of Hsp90
did not differ very much between normal and cancer
cells (Figure 4C). In contrast, survivin was expressed
high in cancer cells (Figure 4C), and the sensitivity of
these cancer cell lines to Antp-TPR correlated with the
expression of this protein (Figure 2A). It is well-known
that anti-apoptotic proteins such as survivin are over
expressed in cancer cells, have significant roles for the
suppression of apoptosis or cell death, and knockdown
of these proteins in cancer cells sensitize to apoptosis
[27,28]. Since cancer cells treated with this hybrid pep-
tide were annexin V and caspase 3, 7 positive as
assessed by flow cytometry, and this peptide also
caused the loss of Hsp90 client proteins including sur-
vivin (Figure 4), we propose the mechanism of action
of Antp-TPR peptide cancer cells killing as follows.
First, Antp-TPR peptide inhibits the Hsp90-Hop inter-
action, and this inhibition affects the correct folding of
these Hsp90 client protein including anti-apoptotic
proteins such as survivin, and this effect might be criti-
cal especially in cancer cells to cause cell death by
apoptotic mechanism. In addition, it was also found
that Antp-TPR peptide did not cause up-regulation of
Hsp70 after treatment with this peptide (Additional
file 2B). Therefore it is suggested that this peptide
might provide an additional advantage compared with
Hsp90-targeted small compounds, since conventional
H s p 9 0A T P a s ei n h i b i t o r si n d u c eac o m p e n s a t o r yu p -
regulation of Hsp70 that likely correlates with the
decrease of anticancer activitya sp r e v i o u s l yr e p o r t e d
[36,37]. It was also demonstrated that Antp-TPR pep-
tide had a significant antitumor activity in mice xeno-
grafted with human pancreatic cancer (BXPC3) causing
loss of CDK4, which is one of Hsp90 client proteins in
tumors. (Figure 5A and 5B), suggesting that this hybrid
peptide administrated intravenously penetrates the
tumor cells, inhibits the interaction of Hsp90 with Hop
interaction, causes the loss of Hsp90 client proteins, and
induces anti-tumor activity in vivo with similar mechan-
ism shown in in vitro analysis. Moreover, histologic
examination suggested that the administrated Antp-
TPR peptide did not cause serious damages to the main
organs (liver, kidney, and lung) and normal tissues, and
any abnormal behaviors or losing of appetite after the
treatment with this peptide was not also observed.
These results suggest that this peptide may not cause
serious side effect after the treatment. Taken together,
these features of the designed Antp-TPR peptide would
offer an attractive new anticancer therapeutic option for
molecular targeted cancer therapy.
Previously we reported the antitumor activities of
immunotoxins, comprising a targeting moiety, such as a
ligand or an antibody to ensure cancer cell selectivity,
and a killing moiety, such as a protein toxin [38-40].
These conventional immunotoxins usually present hur-
dles during clinical use, such as immunogenicity, unde-
sirable toxicity, difficulty in manufacturing, limited half-
life, and production of neutralizing antibodies [41-43].
However, chemical synthesis enables us to produce pep-
tides affordably, with a cost comparable to that of pro-
ducing protein drugs. Moreover, because of the easy
production of peptides, a wide variety of candidate pep-
tides combining moieties for targeting and toxicity can
be tested in preclinical settings.
Recently, Gyurkocza et al.r e p o r t e dan o v e lp e p t i d y l
antagonist of the interaction between Hsp90 and survi-
vin and demonstrated that this peptide causes massive
death of cancer cells but does not reduce the viability of
normal cells [25,26]. In addition, it was also reported
that designed novel TPR modules, which binds to the
C-terminus of Hsp90 with high affinity, decreased HER2
levels in BT474 HER2-positive breast cancer cells,
resulting in the killing of these cells [44]. Taken together
with our current study, these results indicate that pep-
tides targeted at Hsp90 could be potent and novel selec-
tive anticancer agents.
Conclusion
The newly designed hybrid Antp-TPR peptide described
in this study has the molecular features of an inhibitor
of Hsp90-Hop interaction, which is critical for the fold-
ing of several client proteins in cancer cells. Moreover,
the analysis of this peptide in vivo revealed that it dis-
plays significant tumor-suppression activity in mice with
human pancreatic tumor. Because of these features,
Antp-TPR peptide may provide a potent and selective
new cancer therapy, consistent with the use of peptido-
mimetics in targeted cancer therapy [45]. The findings
of this study will assist the further elucidation of cancer
treatment targeting Hsp90.
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Additional file 1: Intracellular penetration of antennapedia helix III
homeodomain (Antp)-conjugated Antp-TPR hybrid peptide. BXPC3
cells were incubated with 10 μM of carboxytetramethyl rhodamine
(TAMRA)-labeled Antp-TPR (Antp-TPR-TAMRA) or TPR (TPR-TAMRA) as
indicated. Cells were then analyzed by phase-contrast (DIC), fluorescence
(TAMRA-red) or merge image (DIC and TAMRA-red). All images were
taken using confocal laser scanning microscopy as described in Methods.
All scale bars are 50 μm.
Additional file 2: Effect of heat shock or Antp-TPR peptide
treatment on the expression levels of Hsp90 or Hsp70 protein in
normal and cancer cells. (A) Western-blot analysis in normal and cancer
cell lines (HEK293T, Caki-1, BXPC3, T47D, and A549) receiving heat shock.
Cell extracts after 2 hr of heat shock treatment (43°C) were examined for
the expression of Hsp90 and Hsp70 by Western-blot analysis using
specific antibodies. (B) Expression levels of Hsp70 in the normal and
cancer cell lines (HEK293T, Caki-1, BXPC3, T47D, and A549) treated with
hybrid Antp-TPR peptide. Cell extracts after treatment with Antp-TPR
peptide were examined for the expression of Hsp70 by Western-blot
analysis using specific antibodies. b-actin was used as the loading
control.
Abbreviations
Hsp90: heat shock protein 90; Hop: p60/Hsp-organizing protein; TPR:
tetratricopeptide repeat; Antp: antennapedia homeodomain sequence; IC50:
the peptide concentration inducing 50% inhibition of control cell growth; PI:
propidium iodide; SPR: surface plasmon resonance; RU: resonance unit; SDS:
sodium dodecyl sulfate.
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